Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark.
It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs.
The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management.
The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism.
The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome.
Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 9, 23 | 0.00 Increased by +100.00% | -0.68 Increased by +100.00% |
| Nov 10, 22 | 0.00 Increased by +100.00% | -0.73 Increased by +100.00% |
| Aug 11, 22 | -11.04 Decreased by -60.70% | -5.84 Decreased by -89.04% |
| May 12, 22 | -5.16 Increased by +10.73% | -6.61 Increased by +21.94% |
| Mar 10, 22 | -6.49 Increased by +33.50% | -6.39 Decreased by -1.56% |
| Nov 11, 21 | -4.61 Increased by +19.97% | -6.31 Increased by +26.94% |
| Aug 12, 21 | -6.87 Decreased by -337.58% | -5.77 Decreased by -19.06% |
| May 12, 21 | -5.78 Decreased by -16.06% | -6.17 Increased by +6.32% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 22 | N/A Decreased by -100.00% | N/A Increased by +100.00% | - - |
| Mar 31, 22 | 15.08 M Decreased by -68.47% | -222.84 M Increased by +7.99% | Decreased by -1.48 K% Decreased by -191.84% |
| Dec 31, 21 | 54.02 M Decreased by -14.74% | -280.26 M Increased by +26.35% | Decreased by -518.86% Increased by +13.62% |
| Sep 30, 21 | 106.41 M Increased by +88.24% | -198.89 M Increased by +12.99% | Decreased by -186.91% Increased by +53.78% |
| Jun 30, 21 | 84.33 M Decreased by -61.85% | -296.81 M Decreased by -410.16% | Decreased by -351.99% Decreased by -1.24 K% |
| Mar 31, 21 | 47.82 M Increased by +285.11% | -242.18 M Decreased by -34.91% | Decreased by -506.46% Increased by +64.97% |
| Dec 31, 20 | 63.36 M Increased by +451.26% | -380.55 M Decreased by -96.49% | Decreased by -600.65% Increased by +64.36% |
| Sep 30, 20 | 56.53 M Increased by +469.70% | -228.57 M Decreased by -101.87% | Decreased by -404.37% Increased by +64.57% |